Drug name - Aggrastat
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(6 months from now) | |
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs
Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) | INJECTABLE;INJECTION | Discontinued |
| EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) | SOLUTION;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.